首页> 外文期刊>Antimicrobial agents and chemotherapy. >High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.
【24h】

High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.

机译:大剂量阿奇霉素与大剂量阿莫西林-克拉维酸酯治疗复发或持续性急性中耳炎患儿。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Infants and young children, especially those in day care, are at risk for recurrent or persistent acute otitis media (AOM). There are no data on oral alternatives to high-dose amoxicillin-clavulanate for treating AOM in these high-risk patients. In this double-blind, double-dummy multicenter clinical trial, we compared a novel, high-dose azithromycin regimen with high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent AOM. Three hundred four children were randomized; 300 received either high-dose azithromycin (20 mg/kg of body weight once a day for 3 days) or high-dose amoxicillin-clavulanate (90 mg/kg divided twice a day for 10 days). Tympanocentesis was performed at baseline; clinical response was assessed at day 12 to 16 and day 28 to 32. Two-thirds of patients were aged < or =2 years. A history of recurrent, persistent, or recurrent plus persistent AOM was noted in 67, 18, and 14% of patients, respectively. Pathogens were isolated from 163 of 296 intent-to-treat patients (55%). At day 12 to 16, clinical success rates for azithromycin and amoxicillin-clavulanate were comparable for all patients (86 versus 84%, respectively) and for children aged < or =2 years (85 versus 79%, respectively). At day 28 to 32, clinical success rates for azithromycin were superior to those for amoxicillin-clavulanate for all patients (72 versus 61%, respectively; P = 0.047) and for those aged < or =2 years (68 versus 51%, respectively; P = 0.017). Per-pathogen clinical efficacy against Streptococcus pneumoniae and Haemophilus influenzae was comparable between the two regimens. The rates of treatment-related adverse events for azithromycin and amoxicillin-clavulanate were 32 and 42%, respectively (P = 0.095). Corresponding compliance rates were 99 and 93%, respectively (P = 0.018). These data demonstrate the efficacy and safety of high-dose azithromycin for treating recurrent or persistent AOM.
机译:婴儿和幼儿,特别是日间护理的儿童,有复发或持续性急性中耳炎(AOM)的风险。没有关于高剂量阿莫西林-克拉维酸口服替代品治疗这些高危患者的资料。在这项双盲,双虚拟多中心临床试验中,我们比较了一种新颖的大剂量阿奇霉素方案与大剂量阿莫西林-克拉维酸盐治疗复发或持续性AOM儿童的疗效。 304名儿童被随机分配。 300例接受大剂量阿奇霉素(每天一次20毫克/千克体重,连续3天)或大剂量阿莫西林-克拉维酸(90毫克/千克,每天两次,共10天)。在基线进行鼓膜穿刺术;在第12至16天和第28至32天评估临床反应。三分之二的患者年龄≤2岁。分别在67%,18%和14%的患者中发现了复发,持续或复发加持续性AOM的病史。从296名意向性治疗患者中的163名(55%)中分离出病原体。在第12至16天,所有患者和2岁以下儿童(分别为85和79%)的阿奇霉素和阿莫西林-克拉维酸的临床成功率均相当(分别为86%和84%)。在第28天至第32天,所有患者(年龄小于或等于2岁)的阿奇霉素临床成功率(分别为72%对61%; 61%; P = 0.047)优于阿莫西林-克拉维酸盐(分别对68%和51%) ; P = 0.017)。在两种方案中,按病原体对肺炎链球菌和流感嗜血杆菌的临床疗效相当。阿奇霉素和阿莫西林-克拉维酸的治疗相关不良事件发生率分别为32%和42%(P = 0.095)。相应的依从率分别为99%和93%(P = 0.018)。这些数据证明了大剂量阿奇霉素治疗复发或持续性AOM的有效性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号